ALL-P-AMBO-2-O-METHYL-P-THIOADENYLYL-(3->5)-2-O-METHYL-P-THIOURIDYLYL-(3->5)-2-O-METHYL-P-THIOCYTIDYLYL-(3->5)-2-O-METHYL-P-THIOADENYLYL-(3->5)-2-O-METHYL-P-THIOURIDYLYL-(3->5)-2-O-METHYL-P-THIOADENYLYL-(3->5)-2-O-METHYL-P-THIOGUANYLYL-(3->5)-2-O-METHYL-P-THIOGUANYLYL-(3->5)-2-O-METHYL-P-THIOADENYLYL-(3->5)-2-O-METHYL-P-THIOADENYLYL-(3->5)-2-O-METHYL-P-THIOADENYLYL-(3->5)-2-O-METHYL-P-THIOCYTIDYLYL-(3->5)-2-O-METHYL-P-THIOADENYLYL-(3->5)-2-O-METHYL-P-THIOCYTIDYLYL-(3->5)-2-O-METHYL-P-THIOCYTIDYLYL-(3->5)-2-O-METHYL-P-THIOADENYLYL-(3->5)-2-O-METHYL-P-THIOADENYLYL-(3->5)-2-O-METHYL-P-THIOADENYLYL-(3->5)-2-O-METHYL-P-THIOGUANYLYL-(3->5)-2-O-METHYL-P-THIOADENYLYL-(3->5)-2-O-METHYL-P-THIOURIDYLYL-(3->5)-2-O-METHYL-P-THIOGUANYLYL-(3->5)-2-O-METHYL-P-THIOADENYLYL-(3->5)-2-O-METHYL-P-THIOURIDYLYL-(3->5)-2-O-METHYL-P-THIOADENYLYL-(3->5)-2-O-METHYL-P-THIOURIDYLYL-(3->5)-2-O-METHYL-P-THIOURIDYLYL-(3->5)-2-O-METHYL-P-THIOURIDYLYL-(3->5)-2-O-METHYL-P-THIOURIDYLYL-(3->5)-2-O-METHYL-P-THIOCYTIDYLYL-(3->5)-2-O-METHYL-P-THIOURIDYLYL-(3->5)-2-O-METHYL-P-THIOURIDYLYL-(3->5)-2-O-METHYL-URIDINE
Cystic Fibrosis
ProQR Therapeuticsnucleic_acidPhase 1/2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 73/ 100
Competitive context
82 Active assets in the Cystic Fibrosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tezacaftor Vertex Pharmaceuticals Incorporated | Phase 4 | A |
Liprotamase Anthera Pharmaceuticals | Phase 4 | BBB |
Ivacaftor Meyer Children's Hospital IRCCS | Phase 4 | BBB |
Lumacaftor Hospices Civils de Lyon | Phase 4 | BBB |
ELEXACAFTOR Meyer Children's Hospital IRCCS | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →